ATE203415T1 - Orales verabreichungssystem von chemischmodifizierten proteinen g-csf - Google Patents

Orales verabreichungssystem von chemischmodifizierten proteinen g-csf

Info

Publication number
ATE203415T1
ATE203415T1 AT95911690T AT95911690T ATE203415T1 AT E203415 T1 ATE203415 T1 AT E203415T1 AT 95911690 T AT95911690 T AT 95911690T AT 95911690 T AT95911690 T AT 95911690T AT E203415 T1 ATE203415 T1 AT E203415T1
Authority
AT
Austria
Prior art keywords
chemically modified
csf
oral administration
modified proteins
administration system
Prior art date
Application number
AT95911690T
Other languages
English (en)
Inventor
Alan D Habberfield
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE203415T1 publication Critical patent/ATE203415T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT95911690T 1994-02-08 1995-02-08 Orales verabreichungssystem von chemischmodifizierten proteinen g-csf ATE203415T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19418794A 1994-02-08 1994-02-08
US37912195A 1995-02-01 1995-02-01
PCT/US1995/001752 WO1995021629A1 (en) 1994-02-08 1995-02-08 Oral delivery of chemically modified proteins

Publications (1)

Publication Number Publication Date
ATE203415T1 true ATE203415T1 (de) 2001-08-15

Family

ID=26889779

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00122148T ATE311908T1 (de) 1994-02-08 1995-02-08 Orale verabreichung von chemisch modifizierten proteinen
AT95911690T ATE203415T1 (de) 1994-02-08 1995-02-08 Orales verabreichungssystem von chemischmodifizierten proteinen g-csf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00122148T ATE311908T1 (de) 1994-02-08 1995-02-08 Orale verabreichung von chemisch modifizierten proteinen

Country Status (11)

Country Link
US (2) US20020099001A1 (de)
EP (2) EP1090645B1 (de)
AT (2) ATE311908T1 (de)
AU (1) AU1916295A (de)
DE (2) DE69521880T2 (de)
DK (2) DK0726778T3 (de)
ES (2) ES2159630T3 (de)
GR (1) GR3036625T3 (de)
IL (1) IL112583A0 (de)
PT (1) PT726778E (de)
WO (1) WO1995021629A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885567A (en) * 1993-10-22 1999-03-23 University Of Connecticut Treatment of infection in fowl by oral administration of avian interferon proteins
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
CN100480266C (zh) 1998-10-16 2009-04-22 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
CA2395713C (en) 2000-01-10 2012-04-10 Maxygen, Inc. G-csf conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
ATE468862T1 (de) 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
EP1633440B1 (de) * 2003-04-15 2008-05-14 Opperbas Holding B.V. Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
ATE544463T1 (de) 2004-11-05 2012-02-15 Univ Northwestern Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US7381805B2 (en) 2005-06-01 2008-06-03 Maxygen Holdings, Ltd. Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
DK2197919T3 (da) 2007-08-27 2014-07-07 Ratiopharm Gmbh Flydende formulering af g-csf-konjugat
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
EP4454664A3 (de) * 2016-11-02 2025-01-22 Board of Regents, The University of Texas System Lösliche filme und verfahren zu deren verwendung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2792862B2 (ja) * 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
DE69120141T2 (de) * 1990-03-28 1996-11-28 Shuji Kojima Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods

Also Published As

Publication number Publication date
WO1995021629A1 (en) 1995-08-17
EP1090645B1 (de) 2005-12-07
EP1090645A2 (de) 2001-04-11
ES2159630T3 (es) 2001-10-16
DE69534676D1 (de) 2006-01-12
ATE311908T1 (de) 2005-12-15
PT726778E (pt) 2001-12-28
EP0726778A1 (de) 1996-08-21
EP1090645A3 (de) 2002-02-27
GR3036625T3 (en) 2001-12-31
IL112583A0 (en) 1995-05-26
AU1916295A (en) 1995-08-29
EP0726778B1 (de) 2001-07-25
US20030185795A1 (en) 2003-10-02
DE69534676T2 (de) 2006-08-17
HK1036214A1 (en) 2001-12-28
DK1090645T3 (da) 2006-03-27
US20020099001A1 (en) 2002-07-25
DE69521880T2 (de) 2002-01-03
ES2251924T3 (es) 2006-05-16
DK0726778T3 (da) 2001-09-24
DE69521880D1 (de) 2001-08-30

Similar Documents

Publication Publication Date Title
DE69521880D1 (de) Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
DK642587A (da) Insulinpraeparat
IL109403A0 (en) Oral drug delivery compositions and methods
ATE380037T1 (de) Verfaheren zur durch rekombinante adeno- assoziierte virus-gerichtete gentherapie
IT8619625A0 (it) Composizioni farmaceutiche per inalazione.
EP2186902A3 (de) Medizinische Präparate zur Behandlung von Alpha-Galaktosidase-A-Mangel
IL112665A0 (en) 5-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
ATE191719T1 (de) Analoge des calcitonin aus lachs, ihre herstellung und ihre verwendung als medizin und als analytische reagentien
RU97113248A (ru) Усовершенствованная лекарственная форма человеческого интерферона-свеча
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
ATE100095T1 (de) 2,2-dimethylchromenderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
IL106591A0 (en) An interferon alpha/beta binding protein,its preparation and pharmaceutical compositions containing it
MY104088A (en) Peptide-drugs compositions containing (alpha)-aminoboroic acid derivatives.
IT8722647A0 (it) Composizione farmaceutica per somministrazione nasale.
ATE223700T1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen
AU609435B2 (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
IT8522989A0 (it) Frazione ottenuta da listeria monocytogenes avente attivita'terapeutica, procedimento per lasua preparazione e composioni farmaceutiche che la contengono.
IL81926A0 (en) Pharmaceutical compositions for the oral administration of active proteins
IT1238210B (it) Esteri del cefamandolo nafato, procedimento per la loro preparazione erelative composizioni farmaceutiche.
IT8611760V0 (it) Siringa per l'anestesia intraligamentosa.
IT1251496B (it) Derivati imidazotiadiazolici ad attivita' diuretica, procedimenti per la loro preparazione e composizioni che li contengono

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification